Background: To study and review the effectiveness of oral care interventions for palliative patients for amelioration of clinical conditions affecting oral cavity.
Methods: Following PRISMA standard, a systematic evaluation of articles published between 2000 and 2021 was undertaken utilising five databases on interventions studies. This comprehensive review consists of randomised controlled trials (RCTs) and specific types of non-randomised studies (NRS) examining oral care interventions for palliative patients. Three independent authors screened search records, identified related studies, extracted data and evaluated risk of bias. The key findings of each study were summarised according to the research questions and data that generated during the data extraction procedure.
Results: Out of the 67 identified studies, seven were included in this review (five RCTs and two NRSs) involving head-and-neck cancer, oral cancer, oral mucositis, xerostomia and individuals with malignant disease. Interventions studied were: Ziziphus honey, artificial saliva, CAM2028-Benzydamine, morphine mouthwash, ketamine mouthwash, bethanechol tablets and caphosol with regular oral-care. The durations of interventions in the included studies were largely short-term (six weeks or less). Overall, six studies revealed good results in support of the intervention, with magnitudes of effect ranging from 13.2-10,110.0%. However, just four researches found significant changes, with magnitudes of effect ranging from 50.0-10,110.0%. Although two of the trials have not revealed significant changes in the results, investigations have indicated a reduction in oral conditions in the group with interventions. Only one trial has not indicated an improvement in oral conditions in the groups which received the interventions.
Discussion: By assessing the efficacy of available oral hygiene interventions for palliative patients, this systematic review can help palliative team finds the viable strategies to apply in controlling oral problems among hospice patients. Even though only four of the seven research found a statistically significant difference, most studies found great effectiveness in favour of intervention.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.21037/apm-22-215 | DOI Listing |
Int J Clin Oncol
January 2025
Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 2-1-1, Idaidori, Yahaba, Iwate, 028-3695, Japan.
Background: The quality of life (QOL) of ovarian cancer patients is often impaired by refractory ascites. Cell-free and concentrated ascites reinfusion therapy (CART) is a palliative treatment for refractory ascites, but adverse events, such as fever, are problematic. Several cytokines have been suggested to be responsible for the adverse events, but they have not been investigated in detail.
View Article and Find Full Text PDFJ Pain Symptom Manage
January 2025
Section of Palliative Care and Medical Ethics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Palliative Research Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; School of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Context: Specialty palliative care remains inaccessible for many with serious illness, especially in rural areas. Telehealth may be one solution.
Objectives: To describe how telehealth increases access to specialty palliative care, describe facilitators and barriers to its use, and summarize evidence of patient benefits.
J Pain Symptom Manage
January 2025
Lien Centre for Palliative Care, Duke-NUS Medical School, Singapore; Programme in Health Services and Systems Research, Duke-NUS Medical School, Singapore.
Context: There has been growing interest in the role of complementary and alternative medicine (CAM) as part of end-of-life care.
Objectives: This study prospectively examined the prevalence, predictors and outcomes of ingestible CAM use among cancer patients in their last year of life in Singapore.
Methods: This study (N=427) utilized data across 12 months (4 time points) prior to patient death.
J Pain Symptom Manage
January 2025
Cambia Palliative Care Center of Excellence at UW Medicine, University of Washington, Seattle, WA; Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA.
Context: Critically-ill patients and their families often experience communication challenges during their ICU stay and across transitions in care. An intervention using communication facilitators may help address these challenges.
Objectives: Using clinicians' perspectives, we identified facilitators and barriers to implementing a communication intervention.
ESMO Open
January 2025
Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Background: Small bowel adenocarcinoma (SBA) is a rare malignancy with few established chemotherapy options and a dismal prognosis. We investigated the expression of claudin 18.2, nectin-4, human epidermal growth factor receptor 3 (HER3), and programmed death-ligand 1 (PD-L1) in SBA to identify potential antibody drug targets and analyzed associated clinicopathological features and prognosis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!